Written By
Sheikh Hasib Ahmed
image credit: Getty Images
The year has experienced its fair share of ups and downs in the ever-changing world of stocks.
image credit: Getty Images
The stock market is currently struggling with the negative effects of increasing interest rates and the ensuing spike in bond yields. However, there is also cause for optimism.
image credit: Getty Images
According to past trends, the fourth quarter of a year is usually the strongest for US equities; therefore, investment bank Goldman Sachs is steadfastly sticking with its earlier year-end price forecast of $4,500 for the S&P 500.
image credit: Getty Images
The stock experts at the bank are choosing the stocks they believe are poised to grow significantly in line with this premise.
image credit: Getty Images
Their recommendations include stocks that might, in certain situations, increase investors' capital by double.
image credit: Getty Images
By any measure, that's a significant gain, and the Goldman analysts have explained why some of their picks might experience a leap that size. Let's look more closely.
image credit: Getty Images
Moderna, a biotech company developing mRNA vaccine technology, will be our first stop.
image credit: Getty Images
You may recall mRNA vaccines from the most recent pandemic; they were developed using this technology, and Moderna was one of the first businesses to commercialize a COVID vaccine.
image credit: Getty Images
Moderna, however, is much more than that; the business has a wide range of vaccines at various phases of development or commercialization.
image credit: Getty Images
Among the 48 projects in the company's pipeline are vaccinations for the flu, RSV, Lyme disease, and even some malignancies.